NVX-CoV2373第四剂同源加强针的免疫原性与安全性
这项II期随机研究在澳大利亚和美国招募18-84岁成人,评估NVX-CoV2373基础免疫后第三、第四剂加强针(间隔6个月)的免疫原性与安全性。1283名入组者中258人随机接受两剂基础免疫,其中104人接种第三剂、45人接种第四剂。第四剂后抗rS IgG和中和抗体较基础免疫后约升高四倍,对奥密克戎BA.5与祖先株应答差距缩小,局部/全身反应性事件在第四剂后趋于平稳,未报告严重或重度不良事件。
要点
- 第四剂NVX-CoV2373后抗rS IgG和中和抗体较基础免疫后约升高四倍。
- 第四剂后局部/全身反应性事件发生率趋于平稳,未报告重度或严重不良事件。
- 对奥密克戎BA.5与祖先株的中和应答差距随加强接种逐步缩小。
核心结论
- 第四剂NVX-CoV2373增强了对祖先株和变异株的免疫原性而未增加反应原性,提示目前可能不需要更新疫苗组分。
研究设计与样本
- II期随机研究(NCT04368988)在澳大利亚和美国招募18-84岁成人,评估NVX-CoV2373基础免疫后第三、第四剂加强针(间隔6个月)。
- 1283名入组者中258人随机接受两剂基础免疫,其中104人接种第三剂、45人接种第四剂。
- 基础免疫在SARS-CoV-2祖先株流行期间接种,第三、第四剂在Alpha和Delta变异株流行期间接种。
- 于接种当天及之后6天评估局部/全身反应原性,并报告非征集性不良事件。
- 于第四剂前及第四剂后14天,采用抗棘突血清IgG和中和试验检测对祖先株及奥密克戎亚系的免疫原性。
主要发现
- 局部/全身反应原性事件发生率在前三剂后升高,第四剂后趋于平稳。
- 第四剂后9%的参与者报告非征集性不良事件,均非重度或严重。
- 加强接种后抗rS IgG水平和中和抗体滴度较基础免疫后约升高四倍。
- 祖先株与奥密克戎BA.5之间的应答差距逐步缩小。
临床怎么用
- 原文结论认为目前可能不需要更新疫苗组分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant spike [rS] protein + 50 µg Matrix-M™ adjuvant; Novavax, Gaithersburg, MD) was evaluated to determine induction of cross-reactive antibodies to variants of concern. A phase II randomized study (NCT04368988) recruited participants in Australia and the United States to assess a primary series of NVX-CoV2373 followed by two booster doses (third and fourth doses at 6-month intervals) in adults 18-84 years of age. The primary series was administered when the SARS-CoV-2 ancestral strain was prevalent and the third and fourth doses while the Alpha and Delta variants were prevalent in AUS and US. Local/systemic reactogenicity was assessed the day of vaccination and for 6 days thereafter. Unsolicited adverse events (AEs) were reported. Immunogenicity was measured before, and 14 days after, fourth dose administration, using anti-spike serum immunoglobulin G (IgG) and neutralization assays against ancestral SARS-CoV-2 strain and Omicron sublineages. Among 1283 enrolled participants, 258 were randomized to receive the two-dose primary series, of whom 104 received a third dose, and 45 received a fourth dose of NVX-CoV2373. The incidence of local/systemic reactogenicity events increased after the first three doses of NVX-CoV2373 and leveled off after dose 4. Unsolicited AEs were reported in 9 % of participants after dose 4 (none of which were severe or serious). Anti-rS IgG levels and neutralization antibody titers increased following booster doses to a level approximately four-fold higher than that observed after the primary series, with a progressively narrowed gap in response between the ancestral strain and Omicron BA.5. A fourth dose of NVX-CoV2373 enhanced immunogenicity for ancestral and variant SARS-CoV-2 strains without increasing reactogenicity, indicating that updates to the vaccine composition may not be currently warranted.
引用
- Alves K, Plested JS, Galbiati S, et al. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373. Vaccine. 2023. PMID: 37271706. doi:10.1016/j.vaccine.2023.05.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。